肝细胞特异性NRF2激活控制脂肪性肝炎的纤维化与癌变
本研究在人类非酒精性脂肪性肝病队列和小鼠模型中探讨KEAP1/NRF2系统的作用。人类肝脏RNA测序显示NRF2激活与炎症分级相关而非脂肪变性分级;小鼠实验表明肝细胞Keap1缺失激活NRF2可减少凋亡、抑制纤维化并降低肿瘤发生。
要点
- NASH患者NRF2激活与炎症分级相关,与脂肪变性分级无关
- 小鼠肝细胞Keap1缺失激活NRF2可减轻纤维化和肿瘤发生
- NRF2激活可能成为NASH相关纤维化和肝癌的保护靶点
核心结论
- 在非酒精性脂肪性肝炎患者中NRF2激活与炎症分级相关而非脂肪变性分级。
- 小鼠功能分析表明慢性肝病中NRF2激活通过改善纤维化、抑制肝细胞癌起始和进展发挥保护作用。
研究设计与样本
- 对人类非酒精性脂肪性肝病队列(n=63)进行肝脏RNA测序并与组织学和临床参数关联。
- 将肝细胞特异性Nemo敲除(NEMOΔhepa)小鼠与肝细胞特异性Keap1敲除(KEAP1Δhepa)小鼠杂交进行功能分析。
主要发现
- 人类肝切片免疫组化显示慢性肝病患者氧化应激增加且NRF2高表达。
- 儿童NAFLD队列肝脏RNA测序显示NRF2激活显著增加并与炎症分级相关,与脂肪变性分级无关,在成人NASH队列中得以证实。
- 小鼠微阵列分析显示Keap1缺失诱导参与谷胱甘肽代谢和异源物应激的NRF2靶基因(如Nqo1)。
- NEMOΔhepa肝脏中谷胱甘肽缺乏在删除Keap1后得到恢复。
- 与NEMOΔhepa肝脏相比,NEMOΔhepa/KEAP1Δhepa肝脏显示凋亡减少、细胞周期调控和DNA复制相关基因显著下调。
临床怎么用
- NRF2激活状态可能作为NASH患者炎症驱动的疾病进展标志物。
- 靶向KEAP1/NRF2轴可能为NASH相关纤维化和肝癌提供保护策略。
局限性
- 人类数据主要来自RNA测序和相关性分析,功能机制主要基于小鼠模型。
- 样本量有限(人类队列n=63),需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In chronic liver diseases, inflammation induces oxidative stress and thus may contribute to the progression of liver injury, fibrosis, and carcinogenesis. The KEAP1/NRF2 axis is a major regulator of cellular redox balance. In the present study, we investigated whether the KEAP1/NRF2 system is involved in liver disease progression in humans and mice. METHODS: The clinical relevance of oxidative stress was investigated by liver RNA sequencing in a well-characterized cohort of patients with non-alcoholic fatty liver disease (n = 63) and correlated with histological and clinical parameters. For functional analysis, hepatocyte-specific Nemo knockout (NEMOΔhepa) mice were crossed with hepatocyte-specific Keap1 knockout (KEAP1Δhepa) mice. RESULTS: Immunohistochemical analysis of human liver sections showed increased oxidative stress and high NRF2 expression in patients with chronic liver disease. RNA sequencing of liver samples in a human pediatric NAFLD cohort revealed a significant increase of NRF2 activation correlating with the grade of inflammation, but not with the grade of steatosis, which could be confirmed in a second adult NASH cohort. In mice, microarray analysis revealed that Keap1 deletion induces NRF2 target genes involved in glutathione metabolism and xenobiotic stress (e.g., Nqo1). Furthermore, deficiency of one of the most important antioxidants, glutathione (GSH), in NEMOΔhepa livers was rescued after deleting Keap1. As a consequence, NEMOΔhepa/KEAP1Δhepa livers showed reduced apoptosis compared to NEMOΔhepa livers as well as a dramatic downregulation of genes involved in cell cycle regulation and DNA replication. Consequently, NEMOΔhepa/KEAP1Δhepa compared to NEMOΔhepa livers displayed decreased fibrogenesis, lower tumor incidence, reduced tumor number, and decreased tumor size. CONCLUSIONS: NRF2 activation in patients with non-alcoholic steatohepatitis correlates with the grade of inflammation, but not steatosis. Functional analysis in mice demonstrated that NRF2 activation in chronic liver disease is protective by ameliorating fibrogenesis, initiation and progression of hepatocellular carcinogenesis. LAY SUMMARY: The KEAP1 (Kelch-like ECH-associated protein-1)/NRF2 (erythroid 2-related factor 2) axis has a major role in regulating cellular redox balance. Herein, we show that NRF2 activity correlates with the grade of inflammation in patients with non-alcoholic steatohepatitis. Functional studies in mice actually show that NRF2 activation, resulting from KEAP1 deletion, protects against fibrosis and cancer.
引用
- Mohs A, Otto T, Schneider KM, et al. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. J Hepatol. 2020. PMID: 33342543. doi:10.1016/j.jhep.2020.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。